Diana Spencer investigates therapies in clinical development for triple-negative breast cancer and asks what future treatments might look like. Triple-negative breast cancer (TNBC) accounts for approximately 15% of all breast cancer cases and is one of the main causes of death in women. However, because these cancers are not driven by any of the three […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!